St Pharm Co (XKRX:237690) LT-Debt-to-Total-Asset: 0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XKRX:237690 St Pharm Co Ltd XKRX:237690
95 GF Score
Price ₩92,700.00
GF Value ₩115,775.72
Valuation Modestly Undervalued
View Full Analysis

What is St Pharm Co LT-Debt-to-Total-Asset?

St Pharm Co XKRX:237690 +0.87% 95 LT-Debt-to-Total-Asset is 0.00 as of Jun. 2026. GuruFocus rates XKRX:237690 with a GF Score™ of 95/100 and a GF Value™ of ₩115,775.72 (Modestly Undervalued).

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. St Pharm Co's long-term debt to total assests ratio for the quarter that ended in Jun. 2026 was 0.00.

St Pharm Co's long-term debt to total assets ratio stayed the same from Jun. 2025 (0.00) to Jun. 2026 (0.00).

St Pharm Co  (XKRX:237690) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

St Pharm Co LT-Debt-to-Total-Asset Related Terms

St Pharm Co LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for St Pharm Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

St Pharm Co LT-Debt-to-Total-Asset Chart

St Pharm Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

St Pharm Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -
XKRX:237690
95GF Score
St Pharm Co Ltd XKRX:237690
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

St Pharm Co LT-Debt-to-Total-Asset Calculation

St Pharm Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=929.219073/788397.850564
=0.00

St Pharm Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2026 is calculated as

LT Debt to Total Assets (Q: Jun. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Jun. 2026 )/Total Assets (Q: Jun. 2026 )
=703.022339/848033.691875
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
St Pharm Co (XKRX:237690) has a LT-Debt-to-Total-Asset of 0.00 as of Jun. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on St Pharm Co and its competitors.
Is St Pharm Co's LT-Debt-to-Total-Asset too high?
St Pharm Co's current LT-Debt-to-Total-Asset is 0.00. Overall, St Pharm Co has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does St Pharm Co's LT-Debt-to-Total-Asset compare to ZTS?
St Pharm Co's LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?
A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on St Pharm Co and its competitors. St Pharm Co's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is St Pharm Co stock overvalued right now?
Based on GuruFocus' analysis, St Pharm Co (XKRX:237690) is currently considered Modestly Undervalued. The stock's GF Value™ is ₩115,775.72, compared to a current price of ₩92,700.00 — trading 19.9% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.00. St Pharm Co's overall GF Score™ is 95/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For St Pharm Co (XKRX:237690), the current LT-Debt-to-Total-Asset is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is St Pharm Co (XKRX:237690) Overvalued in 2026?

Based on GuruFocus' analysis, St Pharm Co stock appears to be undervalued. The current stock price of ₩92,700.00 is trading 19.9% below its estimated GF Value™ of ₩115,775.72. GuruFocus considers St Pharm Co to be Modestly Undervalued.

Key valuation signals for XKRX:237690:

  • LT-Debt-to-Total-Asset: 0.00
  • GF Value™: ₩115,775.72 vs. price of ₩92,700.00 (19.9% below fair value)
  • GF Score™: 95/100

No single metric tells the full story. See the XKRX:237690 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

St Pharm Co Business Description

Address Teheran Road 78, Gangnam-gu, 7F MSA Building, Daechi-dong, Seoul, KOR, 891-43
St Pharm Co Ltd offers custom manufacturing services of Active pharmaceutical ingredients and their intermediates for their use in pharmaceutical development and be compliant to cGMP, requirements. The firm's business areas include commercial manufacturing of new drug development, manufacturing of generic active pharmaceutical ingredients, fine chemical's business and development of oligonucleotide therapeutics. The company's products comprise small molecule active pharmaceutical ingredients, Anti-cancer, Anti- coagulant active pharmaceutical ingredients, etc.
95GF Score

Get the complete analysis for XKRX:237690

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₩92,700.00
Price
₩115,775.72
GF Value